 | Up a level |
Myers, Stephanie (2019) Identification of a Novel Orally Bioavailable ERK5 Inhibitor with Selectivity over p38α and BRD4. European Journal of Medicinal Chemistry, 178. pp. 530-543. ISSN 0223-5234
Myers, Stephanie, Bawn, Ruth H., Bisset, Louise C., Blackburn, Timothy J., Cottyn, Betty, Molyneux, Lauren, Wong, Ai-Ching, Cano, Celine, Clegg, William, Harrington, Ross. W., Leung, Hing, Rigoreau, Laurent, Vidot, Sandrine, Golding, Bernard T., Griffin, Roger J., Hammonds, Tim, Newell, David R. and Hardcastle, Ian R. (2016) High-Throughput Screening and Hit Validation of Extracellular-Related Kinase 5 (ERK5) Inhibitors. ACS Combinatorial Science, 18 (8). pp. 444-455. ISSN 2156-8952
Cancer Research Technology Ltd (2016) Pyrrolcarboxamide derivatives for the inhbition of erk5. PCT/GB2015/052707.
Myers, Stephanie and Collins, Ian (2016) Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapy. Future Medicinal Chemistry, 8 (4). pp. 463-489. ISSN 1756-8919
Myers, S M (2014) Development of extracellular signal-regulated kinase 5 (ERK5) inhibitors for anti-cancer therapy. In: 26th EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics, 18-21 Nov 2014, Barcelona, Spain.
Myers, SM (2012) Hit validation of ERK5 inhibitors: Expectations and challenges. In: ACS 243rd National Meeting and Exposition, 25-29 Mar 2012, San Diego, USA.